News Oct 31, 2023 Debiopharm invests CHF 30 million in Valais amidst workforce surge Debiopharm Research & Manufacturing has announced an investment of over CHF 30 million in a Martigny lab expansion as staff numbers rise from 150...
News Nov 06, 2023 Investors stump up 3.7 million Swiss francs in Onena Medicines Onena Medicines has secured investment of 3.7 million Swiss francs. The portfolio company of the biotech start-up incubator BaseLaunch will there...
Инвестиции в Швейцарии Деловая среда Чем Швейцария может быть Вам полезна? Узнайте в наших материалах.
News Nov 16, 2020 Synendos raises 20 million Swiss francs Synendos Therapeutics has concluded a Series A financing round, raising 20 million Swiss francs. The Basel biotech will use the funds to advance ...
ニュース Nov 20, 2020 スタートアップが2000万スイスフランの調達に成功 スイス・バーゼルのバイオテクノロジー企業Synendos Therapeuticsは、シリーズAの資金調達ラウンドを完了し、2000万スイスフランの調達に成功しました。同社は、調達された資金で脳内の不安に関連する病態の治療に役立てる分子の前臨床研究を進める見込みです。Synendos...
News Feb 23, 2018 Novartis is World’s Most Innovative Biotech Company Basel-based pharmaceutical company Novartis has been recognised as the World’s Most Innovative Biotech Company in 2018 by U.S. media brand Fast C...
News Nov 06, 2023 Abionic and Lascco partner with Fapon for sepsis diagnosis in China Biopôle companies Abionic and Lascco team up with Fapon to harness a groundbreaking biomarker for sepsis detection, enhancing early diagnosis cap...
News Oct 19, 2023 Mimix Biotherapeutics’ breakthrough tissue regeneration treatment receives strategic investment Biel-based Mimix Biotherapeutics announced the closure of a significant investment round, drawing participation from both European and Asian inve...
News Mar 02, 2022 Single-cell technology specialist SEED Biosciences receives FIT boost Through a Tech Growth loan of CHF 400’000, the FIT will fund SEED Biosciences’ sales distribution network expansion in the US to partner with mar...
News Jan 30, 2018 Merck creates R&D company in Geneva Created by Merck Ventures, the German giant’s corporate venture arm, iOnctura is a new company specializing in immuno-oncology.
News Oct 11, 2023 Lonza further extends its ADC manufacturing capabilities in Visp Lonza amplifies ADC production via a robust extension in bioconjugation capacity at its Ibex Dedicate Biopark in Visp, which set to generate 180 ...
News Oct 20, 2023 Lonza expands to manufacture Vaxcyte’s pneumococcal conjugate vaccine Lonza and US clinical-stage vaccine innovation company Vaxcyte have announced an expansion in their partnership to establish a global commercial ...
成功談 Oct 17, 2022 バイオテクノロジーの集積地としてのスイス 横河電機株式会社 微細藻類で新しい食や医療の可能性を開く。YISのミッションは、スイスを拠点に、魅力的なバイオ技術領域を探索し、欧州や日本、インドなどの社内メンバーと一緒に研究活動に取り組み、新規事業を創出することです。
ПОСЛЕДНИЕ НОВОСТИ Jan 30, 2018 «Альпийская биосфера»: Как работает кластер life sciences в Швейцарии Несмотря на то, что в Швейцарии сосредоточены крупнейшие мировые производители фармацевтических препаратов и медицинской продукции (такие как, на...
News Oct 17, 2023 Voltiris, Limula, and Parithera secure Biopôle’s Start-Up Fund Vaud-based start-ups Voltiris, Limula, and Parithera gain momentum in their innovative ventures as they secure vital funding and support from Bio...